Hansa Biopharma AB (publ) (STO:HNSA)
22.38
-0.60 (-2.61%)
Mar 28, 2025, 1:53 PM CET
Hansa Biopharma AB Employees
Hansa Biopharma AB had 135 employees as of December 31, 2024. The number of employees decreased by 33 or -19.64% compared to the previous year.
Employees
135
Change (1Y)
-33
Growth (1Y)
-19.64%
Revenue / Employee
1.27M SEK
Profits / Employee
-5.98M SEK
Market Cap
1.53B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Swedish Orphan Biovitrum AB | 1,840 |
Getinge AB | 11,791 |
Sectra AB | 1,204 |
Camurus AB | 256 |
Medicover AB | 47,000 |
Vitrolife AB | 1,120 |
Vimian Group AB | 1,200 |
Elekta AB | 4,718 |
Hansa Biopharma AB News
- 7 days ago - Hansa Biopharma publishes 2024 Annual and Sustainability Reports - PRNewsWire
- 17 days ago - Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients - PRNewsWire
- 7 weeks ago - Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 3 months ago - Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome - PRNewsWire
- 4 months ago - Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease - PRNewsWire
- 4 months ago - Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome - Business Wire
- 4 months ago - Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome - PRNewsWire